Article info

Download PDFPDF
ANKK1/DRD2 Locus Variants Are Associated With Rimonabant Efficacy in Aiding Smoking Cessation

Authors

  • Charles S. Wilcox From the *Pharmacology Research Institute, Los Alamitos; †UCLA Alcohol Research Center, Psychiatry & Biobehavioral Sciences, Semel Institute for Neuroscience & Human Behavior, Los Angeles; and ‡Pharmacology Research Institute, Newport Beach, CA. PubMed articlesGoogle scholar articles
  • Ernest P. Noble From the *Pharmacology Research Institute, Los Alamitos; †UCLA Alcohol Research Center, Psychiatry & Biobehavioral Sciences, Semel Institute for Neuroscience & Human Behavior, Los Angeles; and ‡Pharmacology Research Institute, Newport Beach, CA. PubMed articlesGoogle scholar articles
  • Nader Oskooilar From the *Pharmacology Research Institute, Los Alamitos; †UCLA Alcohol Research Center, Psychiatry & Biobehavioral Sciences, Semel Institute for Neuroscience & Human Behavior, Los Angeles; and ‡Pharmacology Research Institute, Newport Beach, CA. PubMed articlesGoogle scholar articles
  1. Received May 10, 2011, and in revised form June 21, 2011.
  2. Accepted for publication August 22, 2011.
  3. Reprints: Charles S. Wilcox, PhD, Pharmacology Research Institute, 4281 Katella Ave, Suite #115, Los Alamitos, CA 90720. E-mail: cwilcox{at}priresearch.com.
  4. Funding for this study was provided (internally) by Pharmacology Research Institute and Dr. Noble’s laboratory at UCLA. No other funding was received for this project.
View Full Text

Citation

Wilcox CS, Noble EP, Oskooilar N
ANKK1/DRD2 Locus Variants Are Associated With Rimonabant Efficacy in Aiding Smoking Cessation

Publication history

  • First published December 15, 2015.
Online issue publication 
December 15, 2015

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.